

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> <i>OMB No. 0704-0188</i>	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.				
1. REPORT DATE (DD-MM-YYYY) 23-02-2011		2. REPORT TYPE Journal Article		3. DATES COVERED (From - To)
4. TITLE AND SUBTITLE Measuring the Variability of Treated Bacillus anthracis delta Stern Spores			5a. CONTRACT NUMBER	
			5b. GRANT NUMBER	
			5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mark Guelta, Bruce Voelker, Lauren McNew, Mark Gostomski, Catherine Sabol, Kishna Managaya, Tobert Dorsy, Rebecca Brown, Paul McGregor, Kinberly Osborne, Emily Yost, Peter Emanuel and Laurie Fazehas-Carey			5d. PROJECT NUMBER	
			5e. TASK NUMBER	
			5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ECBC, Aberdeen Proving Ground, MD Battelle Memorial Institute, Aberdeen Proving Ground, MD Science Applications International Corporation, Abingdon, MD Science and Technology Corporation, Edgewood, MD			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSOR/MONITOR'S ACRONYM(S)	
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Distribution Statement: Approved for Public Release; Distribution is unlimited				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT The development of biological detectors for the military and homeland defense 26 relies on the ability to test hardware with biological materials that can be produced reliably 27 and reproducibly. To ensure occupational safety during the development of new devices, 28 the production and testing with biological materials necessitates compromises that include 29 selection of avirulent strains and inactivation using various techniques. The materials and 30 methods selected for production and post-production treatment can greatly influence 31 detection outcomes using sensitive DNA or antibody based systems. The optimal situation 32 would be to reproducibly create biological testing materials that accurately simulate the 33 true pathogen yet carry minimal risk to the scientists and engineers developing the 34 biosensors. In this study, avirulent Bacillus anthracis spores were used to demonstrate the 35 varied outcomes that can be induced by density gradient purification and post-growth 36 inactivation using gamma irradiation. The responses using Quantitative Polymerase Chain 37 Reaction, Electrochemiluminescence, Enzyme-Linked Immunosorbent Assay, 38 Bicinchoninic Acid assay, and protein electrophoresis varied significantly with treatment. 39 Gradient purification removed proteins that interfered with monoclonal and polyclonal 40 antibodies' abilities to form immunocomplexes in Electrochemiluminescent and ELISA 41 assays. Irradiation had a varied effect on qPCR depending on the sample preparation 42 employed and produced a reduced response in Electrochemiluminescent and ELISA 43 assays. Varied results from enumeration techniques show the importance of measuring the 44 dead cellular material and cellular debris contribution to any sample. Production and 45 material treatments need to conform to a yet to be established guideline that can bring 46 uniformity to available biological agent reference materials.				
15. SUBJECT TERMS Bacillus anthracis, detection, sensors, variability				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES 34
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified		
				19b. TELEPHONE NUMBER (include area code) 703.767.3379

1 Title: **Measuring the Variability of Treated *Bacillus anthracis delta* Sterne Spores**

2

3 Running Title: **Variability between Treatments of *Bacillus* Surrogates**

4

5

6 Authors: Mark A. Guelta^{1*}, Bruce Voelker⁴, Lauren McNew¹, Mark Gostomski¹,
7 Catherine Sabol¹, Kishna Mangaya³, Robert Dorsey¹, Rebecca Brown¹, Paul
8 McGregor³, Kimberly Osborne², Emily Yost¹, Peter Emanuel¹, and Laurie
9 Fazekas-Carey¹

10

11 Affiliations: ¹ Edgewood Chemical Biological Center, R & T Directorate, United States Army,
12 Department of Defense, 5183 Blackhawk Road, Aberdeen Proving Ground, MD 21010, ²Battelle
13 Memorial Institute, Battelle Eastern Science & Technology Center (BEST), 1204 Technology
14 Drive, Aberdeen, MD 21001-1228, ³Science Applications International Corporation (SAIC), 1308-J
15 Continental Drive, Abingdon, MD 21009, ⁴Science and Technology Corporation (STC), 500
16 Edgewood Road Suite 205, Edgewood, MD 21040.

17 *Corresponding author: Mark Guelta

18 Phone: 410-436-7310

19 Fax: 410-436-3296

20 Email: mark.guelta@us.army.mil

21

22

23

24

25

26 **The development of biological detectors for the military and homeland defense**
27 **relies on the ability to test hardware with biological materials that can be produced reliably**
28 **and reproducibly. To ensure occupational safety during the development of new devices,**
29 **the production and testing with biological materials necessitates compromises that include**
30 **selection of avirulent strains and inactivation using various techniques. The materials and**
31 **methods selected for production and post-production treatment can greatly influence**
32 **detection outcomes using sensitive DNA or antibody based systems. The optimal situation**
33 **would be to reproducibly create biological testing materials that accurately simulate the**
34 **true pathogen yet carry minimal risk to the scientists and engineers developing the**
35 **biosensors. In this study, avirulent *Bacillus anthracis* spores were used to demonstrate the**
36 **varied outcomes that can be induced by density gradient purification and post-growth**
37 **inactivation using gamma irradiation. The responses using Quantitative Polymerase Chain**
38 **Reaction, Electrochemiluminescence, Enzyme-Linked Immunosorbent Assay,**
39 **Bicinchoninic Acid assay, and protein electrophoresis varied significantly with treatment.**
40 **Gradient purification removed proteins that interfered with monoclonal and polyclonal**
41 **antibodies' abilities to form immunocomplexes in Electrochemiluminescent and ELISA**
42 **assays. Irradiation had a varied effect on qPCR depending on the sample preparation**
43 **employed and produced a reduced response in Electrochemiluminescent and ELISA**
44 **assays. Varied results from enumeration techniques show the importance of measuring the**
45 **dead cellular material and cellular debris contribution to any sample. Production and**
46 **material treatments need to conform to a yet to be established guideline that can bring**
47 **uniformity to available biological agent reference materials.**

48

49 *Bacillus anthracis* is a Category A agent and is the causative agent of the potentially fatal
50 disease “anthrax” (9,7). *B. anthracis* is the gram-positive, non-motile, non-chemolytic, spore-
51 forming bacteria that attracted renewed international attention when transported through the
52 United States mail to members of Congress and the media in November 2001. These mailings
53 and the increased threat from extremist groups have fueled a surge in biological agent sampling
54 and detection defense research that accelerated after the 1991 Gulf War. Currently there are over
55 100 biological detectors and commercially available kits (17,14) with many more under
56 development. The Department of Defense, Department of Homeland Security, and the
57 commercial sector have been actively involved in supporting developmental testing of new
58 biological agent detection equipment (13,3,20,21,25,18).

59 Developmental testing and use of biological detectors for environmental or diagnostic
60 purposes requires the use of biological reference material to properly validate performance.
61 Currently, researchers and instrument developers working to detect *B. anthracis* inadvertently
62 build variability into their results by the use of near neighbor (5,19) *Bacillus* species (*B. cereus*
63 group) or avirulent *B. anthracis* (29) to avoid occupational exposures, and by use of varied
64 growth conditions (1) (media, environmental) and/or preparation procedures.

65 The development and use of chemical and radiological standards is a well established
66 field with multiple reference materials offered for research and development operations around
67 the world. In the arena of biological based standards and references, materials are not as
68 standardized or as rigorously tested as their chemical and radiological counterparts due to the
69 inherent variability of standardizing living material. Biological reference materials are available
70 for purchase, including simulants of bio-warfare agents, but not necessarily marketed as a
71 standard reference material. Because of the relative ease of production, these materials are

72 commonly used as seed stock to produce quantities required for specific testing. Therefore, in
73 addition to variations that may be inherent between the reference materials obtained from
74 multiple sources, the researcher may further compromise the integrity of their materials during
75 their own in-house production and treatment. Additionally, small quantity research grade
76 materials may be processed more stringently than larger productions, thus producing different
77 responses upon presentation to a particular assay. It is also common practice for researchers and
78 developers to use irradiation killed materials (8,30,28,27,2) to meet personnel and/or open air
79 testing safety concerns.

80 The aim of this program was to establish standardized protocols for producing,
81 processing, and analyzing biological reference materials in support of test and evaluation
82 programs. As a result of these studies production methodology and conformance test plans are
83 now under review by the science and technology departments within the Department of Defense
84 agency which funded these studies. Department of Defense programs will benefit by the ability
85 to produce reliable test materials in support of their mission objective to field next generation
86 detection and diagnostic systems. Electrochemiluminescence (ECL), Enzyme-Linked
87 Immunosorbent Assay (ELISA), Quantitative Polymerase Chain Reaction (qPCR) and
88 Bicinchoninic Acid (BCA) assays are included as conformance tests to characterize biological
89 test reference materials. In addition, this program attempted to demonstrate the response
90 commonly used analytical instruments have when testing biological materials that have been
91 prepared using common, but varied, lab practices. This paper describes and summarizes those
92 in-house laboratory results.

93 The material used in this study, *Bacillus anthracis delta* Sterne, lacks both the pXO1 and
94 the pXO2 plasmids (11) (pXO1⁻, pXO2⁻), and is a spore forming bacteria of the *B. cereus* group.

95 The absence of these two plasmids in the *B. anthracis delta* Sterne strain renders the material
96 two steps removed from the lethal *B. anthracis* and provides spores with similar characteristics
97 to other *B. anthracis* strains without the pXO2 plasmid markers. In this study, identically grown
98 spores were subjected to three different, but common, forms of downstream processing. Two
99 processes vary the degree of purification, a triple wash followed by gradient purification versus a
100 single wash only preparation. The third process involved the triple wash plus gradient
101 purification followed by a gamma irradiation kill step. These three preparations were then
102 analyzed using quantitative PCR (qPCR), Electrochemiluminescence (ECL), ELISA,
103 Bicinchoninic Acid protein assay and a protein electrophoresis microchannel assay.

104

105

MATERIALS AND METHODS

106

107

108

109

110

111

112

113

114

115

116

117

Cell/Spore preparation (G Media). *Bacillus anthracis delta* Sterne was obtained from the Unified Culture Collection # BACI056 (Critical Reagents Program, Edgewood, MD) and grown in nine 4L cultures of G-media plus trace metals at 37°C until >95% sporulated. Percent sporulation was determined under phase contrast microscopy by visual count using differential spore stain (Schaeffer-Fulton 5% malachite green). Purity was verified during production by gram staining and phase contrast microscopy at points including seed stock verification, isolation streak, Nutrient Broth inoculum, 2X expansion, pre- and post-growth processing. Media was removed through centrifugation at 6,000 X g for 30 min at 4°C and after, three samples were designated as Ultra-Pure -1, -2, and -3; three as 1X Wash -1, -2, and -3; and three samples as Gamma-Irradiated -1, -2, and -3. The three 1X Wash pellets were washed once with 500 mL of 0.01M ice cold Phosphate Buffer Solution (PBS, Becton Dickinson Difco, Franklin Lakes, NJ), and centrifuged at 4,500 X g for 15 min at 4°C. The supernatant was decanted and

118 the pellets resuspended in 100 mL sterile ice cold 0.01M PBS, and one mL aliquots were
119 prepared and stored at -80°C until analyzed. The Ultra Pure and Gamma Irradiated samples were
120 each washed 3 times and resuspended using the same procedures and volumes. The final washed
121 pellet was resuspended in 100 mL of 70% ethanol (Acros, Morris Plains, NJ) and held at room
122 temperature for 1 h at 150 rpm. The samples were centrifuged at 4,500 X g for 30 min at 4°C.
123 After decanting the supernatant, the pellets were resuspended in 500 mL sterile 0.01M PBS, then
124 heat shocked at 65°C for 1 hr at 150 rpm.

125 **Gradient Purification.** After heat shock, the samples were centrifuged at 4,500 X g for
126 15 min at 4°C. The triple washed, ethanol treated, and heat shocked final pellets were
127 resuspended in a 20% preparation of Renografin-60 (Bracco Diagnostics, Princeton, NJ),
128 overlaid onto a 1:5 ratio of a 50% preparation of Renografin-60 and centrifuged at 10,000 X g
129 for 1 hr at 4°C. The supernatant was decanted and the pellets resuspended in 500 mL ice cold
130 sterile 0.01M PBS. The samples were washed three times in 500 mL ice cold sterile 0.01M PBS
131 centrifuged at 7,000 X g for 30 min at 4°C, and the supernatant decanted. After the final wash,
132 the pellets were resuspended in 100 mL ice cold sterile 0.01M PBS. One mL aliquots of Ultra
133 Pure -1, -2, -3 were prepared and stored at -80°C until analyzed. Gamma irradiated -1, -2, -3
134 were aseptically transferred to three sterile 50 mL conical tubes with 33.3 mL per tube. Spore
135 suspensions were dosed to 50 kGy (5.0×10^6 rads) using a Cobalt-60 gamma irradiation system
136 (J.L. Shepard and Associates, Model 484R-2). One mL aliquots were stored at -80°C until
137 analyzed.

138 Killed *B. anthracis delta* Sterne spores were received from the CRP and used untreated as
139 a reference material in Electrochemiluminescence and ELISA assays. Sample concentration was
140 used as furnished as the referee.

141 **Enumeration by Plating.** Spore concentration (CFU/mL) for each growth was
142 determined using an automated spiral plate technique (15,10), (AP4000 Spiral Biotech, Inc., and
143 Q-Count Advanced Instruments, Norwood, MA) on TSA.

144 **Enumeration by Flow Cytometry.** Spiral plate enumeration results were complimented
145 by the MicroPRO™ automated flow cytometer (Advanced Analytical Technologies, Inc.
146 [AATI], Ames, IA). The MicroPRO, AATI's updated Rapid Biological Detector 3000 platform,
147 uses differential staining to enumerate viable and non-viable organisms. AATI's Total Viable
148 Organism assay kit was used to measure live cell counts which consists of a 3 min incubation of
149 the test sample with 100 µL of a positively charged membrane permeable Nucleic Acid Dye
150 (Molecular Probes, Inc., Eugene, OR) that binds to all living and dead cells. An 8 min
151 incubation follows with 100 µL of BRAG3, AATI's patented non-membrane permeable counter
152 stain that quenches the fluorescence of membrane-compromised cells, and extraneous debris, to
153 ascertain a live cell count for Ultra Pure and 1X Wash treatments. Non-viable cells were
154 counted using AATI's Dead Cell Assay, which consists of a 3 min incubation of the test sample
155 with 100 µL of a positively charged non-membrane permeable dye that stains membrane
156 compromised (non-viable) cells. Test samples were prepared in PB Buffer (AATI, Ames, IA)
157 from stock using serial dilutions to 10^{-4} CFU/mL. Three hundred microliters of each dilution
158 was then added to 2,700 µL of PB Buffer in a 12 x 75 mm culture tube and placed into the
159 sample tray. Samples were treated with Total Viable Organism or Dead Cell stain and the
160 sample was excited at 635 nm. Side scatter and fluorescent intensity measurement of the
161 fluorochrome-labeled cells allowed for quantification of viable or non-viable cells in
162 number/mL.

163 **Quantitative Real-Time Polymerase Chain Reaction (qPCR); Sample Preparation.**

164 Three sample parameters were prepared for qPCR analysis; “Neat” consisted of the sample
165 dilutions prior to centrifugation without treatment (mixed cellular and extra-cellular DNA),
166 “Supernatant” (extra-cellular DNA) was the material removed from the cellular pellet following
167 centrifugation, and FastPrepTM (cellular DNA, treated) was the pelleted and homogenized
168 material collected from the FastPrep system.

169 To yield multiple data sets in the instruments calibration range sample stocks were
170 diluted in PBS (Becton Dickinson difco, Franklin Lakes, NJ), pH 8, from 1.0×10^6 to 1.0×10^3
171 CFU/mL. One milliliter was pelleted by centrifugation at 14,000 X g for 5 min. The supernatant
172 was removed and the pellet was resuspended in 1mL of PBS. The resuspended pellet (FastPrep)
173 was added to Lysing Matrix E tubes (MP Biomedicals, Solon, OH) and homogenized in a
174 FastPrep system (MP Biomedicals, Solon, OH) at 6.5m/s for 1.5 minutes.

175 **Quantitative Polymerase Chain Reaction.** Amplification, data acquisition, and
176 analysis were carried out on an ABI Prism[®] 7900HT Sequence Detection System (Applied
177 Biosystems, Foster City, CA) using a 96-well, standard block format. PCR reactions were
178 performed in duplicate on 4-log serial dilutions. Each reaction well contained 5 μ L of sample and
179 15 μ L of Master Mix [Critical Reagents Program, Aberdeen Proving Ground, MD]. The Critical
180 Reagents Program target three master mix assay for *B. anthracis* is a chromosomal target assay
181 using proprietary primer and probe sequences. The reaction chemistry is optimized for the
182 master mix on the ABI 7900 platform using the standard heating block. The thermocycling
183 profile was: two min at 50°C, 10 min at 95°C, and 45 cycles of 15 s at 95°C followed by 1 min at
184 60°C. Each reaction contained 1.25 U of Platinum *Taq* DNA polymerase that was provided by

185 the Critical Reagents Program. Quantitation was achieved by generating a standard curve from
186 parallel amplification reactions using known amounts (100 pg to 100 fg) of *Bacillus anthracis*
187 *delta* Sterne DNA (Critical Reagents Program, Aberdeen Proving Ground, MD) as template
188 material.

189 The data was analyzed using software provided with the ABI 7900 system. Using the
190 concentrations assigned to each DNA standard, the software constructed a standard curve of
191 Cycle threshold (*C_t*) value versus concentration. Concentration values for the unknown samples
192 were extrapolated from the standard curve by the software. All samples within the calibration
193 limits were normalized to the 1.0×10^6 CFU/mL sample concentration.

194 The *C_t* value (*n*) was used to calculate the genome equivalent (GE). Genomic
195 equivalent is a value determined for a sample specimen using qPCR, numerically equivalent to
196 the copy number of the gene targeted for amplification, reported as a concentration (GE mL⁻¹),
197 which is correlated to concentration (CFU/mL). Genome equivalent is calculated by converting
198 chromosome size to mass using $m = (n) (1.096e^{-21} \text{ g bp}^{-1})$ where *m* = mass of chromosome, *n* =
199 number of nucleotide base pairs (bp), and the constant $1.096e^{-21}$ is derived from Avogadro's
200 number and the average mass of a nucleotide bp (650g mol⁻¹). One gene copy is present per
201 chromosome, which determines the GE by dividing the PCR determined mass of DNA (by
202 qPCR) by the chromosome size (mass).

203 **Protein Quantitation.** Protein quantitation was performed using the Pierce BCA™
204 Protein Assay Kit (Pierce, Rockford, Illinois; Catalog #23225). Bovine Serum Albumin was
205 diluted in 0.01M PBS to concentrations ranging from 1500 to 0 µg/mL to construct a standard
206 curve. Test samples were diluted serially in 0.01M PBS from stock to a concentration of
207 $1.0E+05$ CFU/mL. Bicinchoninic acid (BCA) analysis of samples was performed following the

208 protocol outlined by Smith (26) with 200 μL of BCA working reagent added to 25 μL of sample
209 in a microtiter plate, followed by a 30 min incubation at 37°C. Samples were read and amount of
210 protein quantified at 562 nm using a VersaMax Microplate Reader (MDS Analytical
211 Technologies, Sunnyvale, CA).

212 **Microfluidic Protein Determination.** To determine any presence of extractable antigen
213 1 (EA1) protein (~100kDa), supernatant from each growth treatment was run on the Agilent
214 2100 Protein 230 LabChip according to manufacturer protocol. The Protein 230 LabChip
215 provides data regarding the purity, concentration, and size of proteins within the sample through
216 electrophoresis driven microchannels. A stock sample from each treatment was pelleted at
217 10,000 X g for 5 min at room temperature and 4 μL of the supernatant was transferred to a clean,
218 0.5 mL microcentrifuge tube. The samples were denatured following the manufacturer's
219 protocol. The denatured supernatant was added to the wells on the LabChip in duplicate. The
220 LabChip was run on the Agilent Bioanalyzer according to the settings installed by the
221 manufacturer.

222 **Electrochemiluminescence.** Electrochemiluminescence analysis was performed using
223 the BioVeris M1M Analyzer (BioVeris Corporation, Gaithersburg, MD). Test samples were
224 diluted serially in 0.01M PBS + 0.05% Triton X-100 from stock to concentrations ranging from
225 1.0×10^7 to 1.0×10^3 CFU/mL. Initially, 25 μL of biotinylated antibody (prepared in-house
226 using Molecular Devices Corporation's ImmunoLigand Biotin Label, Prod. # R9002), 25 μL of
227 ruthenium-labeled antibody (prepared in-house using TAG NHS-ester™; BioVeris, Cat. #
228 110036), and 100 μL of sample dilution were combined in 0.75 mL assay tubes placed in a 96-
229 well MINITube holder, and shaken for 10-min at 400 rpm. After shaking, 20 μL of Dynabeads

230 M-280 Streptavidin (DynaL, Cat. # 112.05D) at 1 mg/mL was added to the immunocomplex and
231 Electrochemiluminescent measurements taken in triplicate

232 **Enzyme-Linked Immunosorbent Assay (ELISA).** ELISA samples followed the same
233 dilution scheme used for Electrochemiluminescence analysis. One hundred microliters of
234 capture antibody, diluted to the appropriate concentration in Kirkegaard and Perry Laboratories
235 (KPL) 1X ELISA coating solution (prepared from 10X solution), was added to a 96-well
236 Immulon 2 HB U-bottom microtiter plate. The plate was incubated for 1 hour in a VorTemp
237 Plate Shaker Incubator at 37°C and 400 rpm. After incubation, the plate was washed three times
238 with Abd Serotec 1X ELISA wash buffer using a TECAN 96-well plate washer (TECAN Inc.,
239 Cat. # 16029015). Two hundred microliters of KPL 0.1% milk blocking solution, prepared from
240 2% solution, was added to each well and incubated for 1 hr in the shaking incubator. The plate
241 was then washed three times and 100 μ L of the appropriate antigen concentration diluted in 0.1%
242 milk blocking solution, was added to the wells and incubated for 30 min in a shaking incubator.
243 The plate was washed three times, and 100 μ L of the secondary antibody, diluted to the
244 appropriate concentration in 0.1% milk blocking solution, was added to the wells and incubated
245 for 30 min in the shaking incubator. The plate was washed three times and 100 μ L of the
246 appropriate anti-species Horse radish Peroxidase-labeled conjugate (KPL), diluted at 1:1000 in
247 0.1% milk blocking solution, was added to the wells and incubated for 30 min in the shaking
248 incubator. The plate was then washed three times and 100 μ L of KPL ABTS substrate (Cat. #
249 50-62-00) was added to the plate and incubated at ambient room temperature on an orbital plate
250 shaker for 2 min at 500 rpm. After the 2 min shake, 100 μ L of KPL 1X Stop Solution (prepared
251 from 5X solution, Cat. # 50-85-01) was added to each well. The Optical Density at 405 nm was
252 read on a VersaMax Microplate Reader.

278 Organism. For Gamma Irradiated samples, the Dead Cell value represents the entire compliment
279 of cells in the sample. The dead cell concentration, while a significant contribution to each of
280 the purification treatments, does not indicate a significant difference between treatments. The
281 irradiated treatment dead cell contribution is significantly different.

282 **Comparison of MicroPRO and AP4000 Data.** The MicroPRO and AP4000 both
283 measure cell concentrations in a diluted suspension and are therefore open to comparison even
284 though their methods of arriving at their respective values differ. The MicroPRO can count
285 single cells it determines to be viable through differential staining, but cannot assure that the
286 cells are the target organism, or that the cell it designates as viable would in fact grow when
287 presented with appropriate growth conditions. A significant difference is noted between the
288 Irradiated Dead Cell and the spiral plate results observed in Figure 2.

289 **Quantitative Polymerase Chain Reaction.** Three preparations of each spore treatment
290 were prepared to observe differences in extra-cellular DNA contributions as a function of spore
291 treatment. Sample limit of detection was established nominally at 1.0×10^3 CFU/mL based on
292 cycle time of 0.05 pg calibration standard. Genome Equivalents of all dilutions was normalized
293 to results of the 1.0×10^6 CFU/mL dilutions and results pooled by treatment are presented in
294 Figure 3.

295 The FastPrep qPCR procedure is the high efficiency, baseline preparation for our qPCR
296 samples. Genome Equivalents results for Ultra Pure indicate that unprocessed (Neat) samples of
297 strictly cellular (spore) and extracellular DNA (sup) represent only 5.42 and 4.26 percent,
298 respectively, of the FastPrep mixed DNA sample, indicating Genome Equivalents yield for non-
299 FastPrep prepared spores is low, around 5 percent. Conversely, the cellular (spore) and
300 extracellular DNA for the 1X Wash treatments represents 60.7 and 49.0 percent, respectively, of

301 the FastPrep mixed DNA sample. This indicates a much higher Genome Equivalents yield for
302 non-FastPrep prepared qPCR samples likely due to the ease of measuring DNA in the 1X Wash
303 samples containing a greater percentage of vegetative cells and extra-cellular DNA. An
304 interesting comparison is that of the Ultra Pure versus Gamma Irradiated “Neat” (cellular)
305 Genome Equivalents. The irradiation treatment apparently allows DNA to be more easily
306 extracted from intact spores (Neat, 16.4 %) without increasing extra-cellular (Supernatant,
307 4.87%) DNA, indicating that the spores may be weakened by irradiation, though not ruptured.

308 Ideally the FastPrep results for each post growth treatment should be the same. Analysis
309 of Variance results of FastPrep preparations indicate significant differences ($P= 0.0027$) between
310 Ultra Pure and 1X Wash samples. Other FastPrep comparisons, Ultra Pure vs Gamma Irradiated
311 and 1X Wash vs Gamma Irradiated are not different. Significant differences exist between Ultra
312 Pure, 1X Wash, and Gamma Irradiated post growth culture treatments using the Neat qPCR
313 sample treatment. Supernatant preps of the Ultra Pure and 1X Wash treatments are significant,
314 while differences between Ultra Pure and Gamma Irradiated are not. The number of
315 observations ranged from 42 (Supernatant/Gamma Irradiated) to 74 (FP/Ultra Pure).

316 **Protein Determination.** Results for Bicinchoninic Acid protein varied widely at lower
317 concentrations prompting a search for a sample concentration level that yielded consistent
318 results. Reliability using this assay on *B. anthracis delta* Sterne spores began at a protein
319 concentration of approximately 15- $\mu\text{g}/\text{mL}$. No matter which post growth treatment tested, the
320 Bicinchoninic Acid assay on *B. anthracis delta* Sterne spores was not reliable below a sample
321 threshold of 1.0×10^7 CFU/mL. There is no effect of treatment on data reliability. Data from the
322 serial dilutions were normalized to 1.0×10^7 CFU/mL for comparison and are represented in
323 Figure 4.

324 Bicinchoninic Acid Analysis of Variance results indicate a significant difference in
325 protein concentrations between “1X Wash” and the two other post growth treatments. This
326 demonstrates the effect of decreased post growth washings and added renografin purification on
327 total protein available to this assay. There was no difference between “Ultra Pure” and “Gamma
328 Irradiated” treatments, indicating gamma irradiation of Ultra Pure spores in suspension had no
329 effect on protein results for the assay used.

330 **Microfluidic Protein Determination.** The Protein 230 LabChip reveals a band at
331 approximately 100 kDa in the Ultra Pure and 1X Wash treatments samples (Figure 5). The band
332 is not present in the irradiated samples, owing to the destructive process of gamma irradiation.
333 The 100 kDa band observed is likely due to the presence of the EA1 (extractable antigen 1)
334 protein, or its closely related S-layer protein, SAP (surface array protein).

335 **ElectroChemiluminescent Assay.** Typical test sample concentrations ranged from $1.0 \times$
336 10^3 to 1.0×10^7 CFU/mL as refereed by AP4000. Net assay results in Electrochemiluminescent
337 units are presented after subtraction of background (Figure 6). Response was linear through 1.0
338 $\times 10^6$ CFU/mL with a limit of detection at 1.0×10^4 CFU/mL as mean background plus 3X Std-D
339 for all samples.

340 Analysis of Variance was conducted for all treatments at 1.0×10^5 CFU/mL sample
341 concentration, well within the linear response range for all samples. Differences were measured
342 between Ultra Pure and all other samples, as well as 1X Wash and all other samples. No
343 differences were observed between the Gamma Irradiated and Critical Reagents Program
344 reference material. A decreased response (about half) was observed in the 1X Wash treatment
345 samples compared to Ultra Pure samples. This decreased response in 1X Wash treatment is
346 likely the result of higher EA1 and/or SAP protein content resulting from the decreased degree of

347 post growth purification compared to the Ultra Pure Treatment. The response to “Gamma
348 Irradiated” and Critical Reagent Program samples are significantly lower than Ultra Pure and 1X
349 Wash samples, but not significantly different from each other. The comparison between “Ultra
350 Pure” and “Gamma Irradiated” treatments indicates irradiation has a significant effect on a
351 sample’s Electrochemiluminescent assay response.

352 **ELISA.** The Ultra Pure samples yielded the highest response while the Critical Reagents
353 Program Reference material showed the lowest. The Ultra Pure samples showed the highest
354 response with an OD₄₀₅ above 2.0 with 1X Wash, the next highest, at 1.5 for sample
355 concentrations of 1.0×10^6 CFU/mL (not shown). Gamma Irradiated and Critical Reagents
356 Program samples did not illicit a response above OD₄₀₅ of 1.0 Ultra Pure to 1.0×10^6 CFU/mL.

357 Response was linear through 1.0×10^5 CFU/mL with a limit of detection at 1.0×10^4
358 CFU/mL for Ultra Pure and 1X Wash samples, and a limit of detection at 1.0×10^5 CFU/mL for
359 Gamma Irradiated samples. Analysis of Variance between treatments used data that was clearly
360 in the linear range for all samples (1.0×10^5 CFU/mL, Figure 7). Analysis of Variance at $1.0 \times$
361 10^5 CFU/mL indicated differences between Ultra Pure and all other samples, as well as 1X Wash
362 and all other samples, similar to the patterns that were observed in the Electrochemiluminescent
363 assay data. No differences were observed between the Gamma Irradiated and Critical Reagents
364 Program reference material. The greatest difference observed was between the Ultra Pure and
365 Gamma Irradiated treatments. From Figure 7, the 1X Wash treatment’s Optical Density
366 response is observed to be significantly lower than the Ultra Pure treatment’s response most
367 likely resulting from higher EA1 or SAP protein content due to less post growth purification of
368 the target *B. anthracis delta* Sterne spores. All growth treatments had a linear response up to a

369 sample concentration of 1.0×10^5 CFU/mL with goodness of fit (R^2) above 0.99. Change in
370 response became non-linear at Optical Density above 1.0.

371 **DISCUSSION**

372 **Enumeration.** Dilution plating of bacteria is considered a standard for enumeration and
373 was used to determine the referee concentrations used in our Conformance Test Plan testing, it
374 however cannot account for non-living contributions in a sample. Dilution plating confirmed a
375 100% gamma irradiation kill rate in a 33 mL suspension. This is consistent with earlier studies
376 (8,7) that found 25 Gy and 28 Gy were sufficient and our data adds to kill rates for larger
377 volumes. From Figure 2, comparison of plating and MicroPRO™ Total Viable Organism and
378 Dead Cell results indicate these methods agreed well with plating of Ultra Pure and 1X Wash
379 treatments. Dead Cell analysis used for Gamma Irradiated samples did not agree with pre-
380 irradiation plating results. The qPCR FastPrep results (Figure 3) validate the AP4000
381 enumeration results over the MicroPRO dead cell analysis. The Total Viable Organism vs Dead
382 Cell results for live samples is valuable for measuring any contribution of dead organisms
383 (Figure 1) to an analytical technique, like qPCR, that doesn't differentiate between live or dead.
384 According to MicroPRO analysis, the dead component of Ultra Pure and 1X Wash samples are
385 consistent from a low of 12.2% for 1X Wash-3 to a high of 15.5% for Ultra Pure-1 (not shown).
386 Sporulated bacteria have long been known to be more resilient (4) than vegetative forms. Left-
387 over, unaccounted for, dead vegetative material in a sample can induce a significantly different
388 response under analysis. Determining this proportion of samples considered live is an important
389 component of sample validation.

390 **Determination of Genomic Equivalents.** Results of qPCR analysis shown in Figure 3
391 clearly show differences associated with post growth sample treatment and qPCR preparation.

392 The relative ratios of Neat and Supernatant GE are indicative of post growth purification.
393 Extracellular DNA make up the majority of the GE measured in the Neat or no processing
394 sample. The relatively small difference between the Neat and Supernatant samples once
395 processed with FastPrep make up the entire cellular DNA GE response. The Neat and
396 Supernatant preps of the qPCR 1X Wash sample Genome Equivalents are significantly higher
397 than Ultra Pure and Gamma Irradiated samples. The elevated levels of cellular (pelleted) DNA
398 (grey, figure 3), analyzed without qPCR pretreatment (beating or extraction), are indicative of
399 non-spore, vegetative carryover from limited washings; fractured or poorly developed spore
400 coats; and to a lesser degree, fully formed spores. The Supernatant (crossed, figure 3)
401 pretreatment represents only extra-cellular DNA that is difficult to remove requiring additional
402 washings or gradient purification. Differences in Neat prep results between Ultra Pure and
403 Gamma Irradiated samples indicate spores are further weakened or fractured by γ -irradiation,
404 thus allowing quantitation as an untreated preparation. Differences between Ultra Pure and
405 Gamma Irradiated Supernatant preparations are not significant, indicating γ -irradiation treatment
406 may weaken or fracture spores but do not produce added extracellular DNA.

407 Our comparison of the Gamma Irradiated vs non-Gamma Irradiated FastPrep samples
408 disagrees with Daupin (8) who suggests that irradiation decreases the limit of detection using
409 real-time PCR. Our data indicate no change in GE between the Ultra Pure and Gamma
410 Irradiated FastPrep samples. Our data do indicate increases in available cellular DNA when no
411 PCR pre-treatment is used, suggesting the previous studies (8) method of no pre-treatment of
412 spore samples was inefficient and irradiation, a pre-treatment in this case, increases that
413 efficiency. Daupin's (8) speculation that temperature control during irradiation affects *B.*
414 *anthracis delta* Sterne detection limits is a valid concern that should be further addressed.

415 **Protein Analysis.** Analysis using the Bicinchoninic Acid method on spores indicated the
416 assay is not particularly sensitive below a Limit of Detection of 1.0×10^7 CFU/mL. Data
417 indicate significant protein carryover in 1X Washed samples. Gradient purification significantly
418 lowered total protein content in Ultra Pure and Gamma Irradiated treatments. Comparison of
419 Ultra Pure vs Gamma Irradiated samples show no significant difference. Total protein available
420 to the assay is unaffected by irradiation treatment at the level of treatment used.

421 **Protein 230 Chip.** Chip data from Figure 5 indicate the presence of extractable antigen 1
422 (EA1) or surface array proteins (SAP) in Ultra Pure and 1X Wash post growth treatments. Both
423 EA1 and SAP are known to be proteins attached to vegetative cells weighing approximately
424 100kDa. These proteins were not detected in Gamma Irradiated samples at the concentrations
425 tested, indicating these proteins are destroyed during irradiation or at least lowered to
426 undetectable levels. Limit of Detection is not known for these proteins using this assay. Our
427 findings are consistent with those of Williams and Turnbough (29), and Farchaus et al.(11) who
428 reported that EA1 is more frequently associated with vegetative cell material that has not been
429 completely removed from spore preparations, while SAP is often associated both with cell
430 material and in the supernatant of the preparation (22). Due to the similarity in size and
431 sequence of these two proteins, further work is required to determine the specific identification
432 of the 100 kDa band observed through protein chip analysis. Given our analysis used only
433 supernatant preps at room temperature, our 100kDa bands are likely SAP. Further extraction
434 would likely reveal higher concentrations of the combined proteins. Regardless, the presence of
435 either of these proteins indicates that vegetative cell material is likely present in the Ultra Pure
436 and 1X Wash preparations and may play a role in other biodetection assays.

437 **ElectroChemiluminescence.** The difference in Electrochemiluminescent assay response
438 between Ultra Pure and 1X Wash (Figure 6) may be the result of increased EA1 or SAP protein
439 concentration in the 1X Wash treatment samples due to purification treatments. The monoclonal
440 reporter antibody used in this study's Electrochemiluminescent assay was raised against spores
441 with some leftover vegetative material, and thus believed to cross-react with EA1. Therefore, if
442 EA1 is present in a sample, it competes with the target *B. anthracis delta* Sterne spores bound to
443 the polyclonal capture antibody (already bound to a magnetic dynabead) to attract and bind the
444 reporter antibody and form the sandwich immuno-complex. This, in turn, leads to a decreased
445 number of immuno-complexes being formed and anchored to the magnet in the BioVeris M1M's
446 flow cell. When the flow cell is preconditioned with the assay buffer necessary to drive the
447 Electrochemiluminescent assay reaction, the detector antibodies bound to EA1 are washed out of
448 the flow cell, leaving only those immuno-complexes that formed properly and anchored to the
449 magnet in the flow cell (via a magnetic dynabead) to yield a Electrochemiluminescent response.
450 The further decreased response of Gamma Irradiated samples compared to the Ultra Pure and 1X
451 Wash treatments may also be the result of poor immuno-complex formation. Changes to
452 exosporium appearance have been previously noted following irradiation (23). Removal and/or
453 partial destruction of epitopes (sites on the exosporium where antibodies bind to the spore) by
454 irradiation treatment would greatly decrease assay response in an Electrochemiluminescent assay
455 that utilizes a monoclonal reporter antibody whose binding options by nature are very specific
456 and/or limited. Dang (7) also reported decreased enzymatic assay responses to *B. anthracis delta*
457 Sterne spores after irradiation and proposed destruction of surface layer epitopes as cause for the
458 decrease in assay response.

459 **ELISA.** The ELISA response across the concentrations tested is presented in Figure 7.
460 The two antibodies used in the ELISA assay were the same as those used in the
461 Electrochemiluminescent assay. In the ELISA assay, the EA1 or SAP protein once again
462 competed with the target *B. anthracis delta* Sterne spores to attract and bind the detector
463 antibody to form the sandwich immuno-complex, ultimately leading to a decrease in response.
464 Numerous plate washes during the ELISA process removed a lot of malformed immuno-
465 complexes, leaving fewer properly formed immuno-complexes to produce a response. As an
466 alternate interferent, irradiation treatment led to a further decreased Optical Density response
467 (and subsequent Limit of Detection) compared to the Ultra Pure and 1X Wash treatments. As
468 was observed in the Electrochemiluminescent results, irradiation may remove or destroy
469 antibody binding sites on the exosporium leading to a decrease in ELISA response (7). Our
470 ELISA findings are consistent with Dang (7), who also measured decreases in ELISA response
471 to irradiated samples, but interestingly enough, saw an increase in ELISA response to autoclaved
472 spores and extracellular antigens. Conversely, Daupin (8) reported mixed results when using
473 direct, indirect, and sandwich ELISA. Certainly direct comparison using identical deactivation
474 and detection methods on the same virulent and non-virulent strains is warranted.

475 Our data has demonstrated response differences observed using total Protein, qPCR,
476 ELISA, and Electrochemiluminescent assays. The identification of EA1/SAP proteins with the
477 Protein 230 Labchip and removal of these proteins by gradient purification are demonstrated as
478 important steps in quality antigen preparation. Gradient purification demonstrated a great
479 improvement in spore sample quality in DNA and enzymatic assays through protein and
480 extracellular DNA removal. Irradiation treatment may change spore surface characteristics that
481 can lower enzymatic assay response yet increase DNA detection when analyzing untreated qPCR

482 samples. Assays that quantify *B. anthracis delta* Sterne using qPCR must consider the cellular
483 versus extra-cellular disposition of sample DNA. Additionally, live versus dead cell contribution
484 should be a first consideration when evaluating a material as a concentration reference.

485 Data is also presented in the literature demonstrating differences in assay detection based
486 on purity, inactivation, and virulence (29,8,7) of *B. anthracis delta* Sterne. Uniform
487 conformance testing and standardized protocols for post growth treatment of sporulated test
488 materials are needed to bring the use of biological test materials into a uniform quality system.

489

490

ACKNOWLEDGEMENTS

491

492 The authors would like to thank Dan Carmany of Battelle and Darrel Menking for
493 technical consultations, and Jude Height for critical review of this manuscript. We thank Corkey
494 Smith and Janett Stein for assistance with library services. We would like to acknowledge Ngai
495 Wong at the Defense Threat Reduction Agency for technical consultations and funding of this
496 study.

497

498

REFERENCES

- 499 1. **Almedia, J.L., L. Wand, J.B. Morrow, and K.D. Cole.** 2006. Requirements for the
500 development of *Bacillus anthracis* spore reference materials used to test detection systems, J,
501 Res. Natl. Inst. Stand. Technol. 111:205-217.
- 502 2. **Almeida, J.L., B. Harper, and K.D. Cole.** 2008. *Bacillus anthracis* spore suspensions:
503 determination of stability and comparison of enumeration techniques. J. Appl. Microbiol.
504 104:1442-1448.

- 505 3. **Anderson, D.O. and A.J. Mohr.** 2004. Abbreviated test report for technology readiness
506 evaluation 2 for networked biological point detectors, WDTC-TR-03-134 (West Desert Test
507 Center, U.S. Army Dugway Proving Ground, Dugway Utah) AD-B297339
508 UNCLASSIFIED.
- 509 4. **Belgrader, P., D. Hansford, G.T.A. Kovacs, K. Venkateswaran, R. Mariella Jr. F.**
510 **Milanovich, S. Nasarabadi, M. Okuzumi, F. Pourahmadi, nd M.A. Northrup.** 1999. A
511 minisonicator to rapidly disrupt bacterial spores for DNA analysis. *Anal. Chem.* 71, 4232-
512 4236.
- 513 5. **Borthwick, K.A.J., T.E. Love, M.B. McDonnell and W.T. Coakley.** 2005. Improvement of
514 immunodetection of bacterial spore antigen by ultrasonic cavitation, *Anal. Chem.* 77:7274-
515 7245.
- 516 6. **Burns, M.J., G.J. Nixon, C.A. Foy, and N. Harris.** 2005. Standardization of data from real-
517 time quantitative PCR methods evaluation of outliers and comparison of calibration curves.
518 *BMC Biotechnology* 5:31, 2005.
- 519 7. **Dang, J.L., K. Heroux, J. Kearney, A. Arasteh, M. Gostomski, and P.A. Emanuel.** 2001.
520 *Bacillus* spore inactivation methods affect detection assays. *Appl. Environ Microbiol* 67:8
521 3665-3670.
- 522 8. **Daupin, L.A., B.R. Newton, M.V. Rasmussen, R.F. Meyers, and M.D. Bowen.** 2008.
523 Gamma irradiation can be used to inactivate *Bacillus anthracis* spores without compromising
524 the sensitivity of diagnostic assays. *Appl. Environ. Microbiol.* 74:4427-4433.
- 525 9. **Department of Health and Human Services,** 2009. Bioterrorism Agents/Diseases, CDC,
526 <http://www.bt.cdc.gov/agent/agentlist-category.asp>.

- 527 10. **Edmunds, J. M., P.J. Collett, E.R. Valdes, E.W. Skowronski, G.J. Pellar, and P.A.**
528 **Emanuel.** 2009. Surface sampling of spores in dry-deposition aerosols. *Appl. Environ.*
529 *Microbiol.* **75**:39-44.
- 530 11. **Farchaus, J.W., W.J. Ribot, M.B. downs, and J.W. Ezzell,** 1995. Purification and
531 Characterization of the Major Surface Array Protein from the Avirulent *Bacillus anthracis*
532 Delta Sterne-1, *J. Bacteriol* 177:9 2481-2489.
- 533 12. **Fouet, A., S. Mesnage, E. Tosi-Couture, P. Gounon, and M. Mock.** 1999. *Bacillus*
534 *anthracis* surface: capsule and S layer. *J Applied Microbiol* **87**, 251-255.
- 535 13. **Fox, A., and 17 other attendees.** 2002. Report of the “Bioterrorism Workshop”, *J.*
536 *Microbiol. Meth.* 51:247-254.
- 537 14. **Fruchey, I.R. and P.A. Emanuel.** 2006. Market survey: biological detectors, ECBC-SP-019
538 (Edgewood Chemical Biological Center, Aberdeen Proving Ground, Md) AD-A456146.
539 Unclassified
- 540 15. **Gilchrist, J.E., J.E. Campbell, C.B. Donnelly, J.T. Peeler, and J.M. Delaney.** 1973. Spiral
541 plate method for bacterial determination, *Appl. Microbiol.* **25**:244-252.
- 542 16. **Grubb’s Test for Outliers,** 2006. 1.3.5.17., NIST/SEMATECH e-Handbook of statistical
543 methods, <http://www.itl.nist.gov/div898/handbook/2006>.
- 544 17. **Guide for the Selection of Biological Agent Detection Equipment for Emergency First**
545 **Responders,** 2007. Vol. 1&2, DHS Guide 101-06 2nd Ed.
- 546 18. **Kournikakis, B., C. Bateman, and J.W. Cherwonogrodzky.,** 2000. Characterization of 21
547 strains of *Bacillus anthracis*. DRES-TM-2000-157 (Defence Research Establishment, Suffield
548 Alberta) AD-A387399. UNCLASSIFIED.


- 549 19. **Laflamme, C., S. Lavigne, J. Ho, and C. Duchaine.** 2004. Assessment of bacterial
550 endospore viability with fluorescent dyes. *J. Appl. Microbiol.* 96:684-692.
- 551 20. **Luo, S. and A.J. Mohr.** 1997. Abbreviated test report for laser-induced fluorescence- data
552 acquisition for agents of biological origin, DPG-TR-97-049-PT-1 (West Desert Test Center,
553 Dugway Proving Ground, Utah) AD-B229960, UNCLASSIFIED.
- 554 21. **Luo, S. and A.J. Mohr.** 1998. Abbreviated test report for mass spectrometer biological
555 profiling, DPG-TR-98-094-PT-4 (West Desert Test Center, Dugway Proving Ground, Utah)
556 AD-B241-544, UNCLASSIFIED.
- 557 22. **Mesnage, S. E. Tosi-Couture, M. Mock, P. Gounon and A. Fouet,** 1997. Molecular
558 characterization of the *Bacillus anthracis* main S-layer component: evidence that it is a major
559 call-associated antigen. *Mol Microbiol* 23: 1147-1155.
- 560 23. **Philips, A.P., A.M. Campbell, and R. Quinn.** 1988. Monoclonal antibodies against spore
561 antigens of *Bacillus anthracis*. *FEMS Microbiol. Immunol.* 47:169-178.
- 562 24. **Schumacher, W.C., C.A. Storozuk, P.K. Dutta, and A.J. Phipps.** 2008. Identification and
563 characterization of *Bacillus anthracis* spores by multiparameter flow cytometry. *Appl*
564 *Environ Microbiol* 74:16 5220-5223.
- 565 25. **Sequeira, A.** 2002 & 2003. Aptamer-enhanced biorecognition reagent system, (Omnisite
566 Biodiagnostics Inc. Austin TX)
567 <https://cbnet.apgea.army.mil/org/rda/od/odi/LIBRARY/pdf/b288845.pdf> AD-B288845, AD-
568 B307292, UNCLASSIFIED.
- 569 26. **Smith, P.K., R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano,**
570 **E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk.** 1985. Measurement of protein
571 using Bicinchoninic Acid. *Anal. Chem.* 150:75-85.

- 572 27. **Stopa, P.J.**, 2000. The flow cytometry of *Bacillus anthracis* spores revisited. Cytometry
573 41:237-244.
- 574 28. **Stopa, P.J., S.A. Sincock, C.R. Johnson.** 2000. Evaluation of sensitive membrane antigen
575 rapid test (SMART) tickets for the detection of biological materials, ECBC-CR-002 (Science
576 and Technology Corp. Hampton, VA) AD-B252644. UNCLASSIFIED.
- 577 29. **Williams, D.D. and C.L. Turnbough, Jr.** 2004. Surface layer protein EA1 is not a
578 component of *B anthracis* spores but is a persistent contaminant in spore preparations, J.
579 Bacteriol 186;2 566-569.
- 580 30. **Winters, D.R., D.D. Martin, and B.G. Harper.** 2003. Abbreviated test report for the
581 Defense Threat Reduction Agency laboratory report. WDTC-TR-02-077 (West Desert Test
582 Center, Dugway Proving Ground, Utah) AD-B286531 UNCLASSIFIED.
- 583

584 TABLE 1. Data for Spiral Plate Colony Enumeration of *B. anthracis delta* Sterne Flask Growths.
585

Sample ID	Mean (CFU/mL)	Sample ID	Mean (CFU/mL)
UP 1	1.16×10^8	Irrad 1	1.70×10^6
UP 2	1.72×10^8	Irrad 2	1.00×10^7
UP 3	1.25×10^8	Irrad 3	8.41×10^6
1X 1	1.00×10^8		
1X 2	1.70×10^8		
1X 3	1.34×10^8		


586
587



588
589


590 FIG. 1. MicroPRO Total Viable Organism and Dead Cell Assay Results, Mean and Standard
591 Error (bars), for all Prepared *B. anthracis delta* Sterne Treatments. Ultra Pure and 1X Wash
592 were enumerated using the Total Viable Organism (clear) and, Dead Cell (shaded) assays.
593 Gamma Irradiated samples were enumerated with Dead Cell assay only. Data is presented for
594 treatment mean and standard deviation.

595
596




597
 598
 599
 600
 601
 602
 603
 604

FIG. 2. Comparison of Mean values for *B. anthracis delta* Sterne Treatments from MicroPRO (clear) (Total Viable Organism and Dead Cell) and AP4000 (shaded) Analysis. MicroPRO Total Viable Organism analysis is represented for Ultra Pure and 1X Wash treatments, Dead Cell analysis is represented for Gamma Irradiated treatment.



605
 606
 607
 608
 609
 610
 611
 612


FIG. 3. Comparisons of qPCR Results for Growth Treatment and qPCR Sample Preparation Treatments. FastPrep (dotted) represents bead-beaten pelleted re-suspension samples. Neat samples (grey) are untreated (cellular and extra-cellular DNA) samples; Supernatant (crossed) represent extra-cellular DNA, un-beaten samples. Bars are standard error.



613
614


615 FIG. 4. Bicinchoninic Acid protein assay results for mean of each treatment of *B. anthracis delta*
616 Sterne post growth treatments at sample concentration of 1×10^7 CFU/mL. Bars indicate
617 standard error. The number of observations for Ultra Pure, 1X Wash, and Gamma Irradiation are
618 49, 25, and 30 respectively.

619
620



621
 622
 623 FIG. 5. Protein 230 LabChip results for Ultra Pure, 1X Wash and Gamma Irradiated post
 624 treatments. Bands at 97 kDa for Ultra Pure and 1X Wash samples represent protein
 625 concentrations of 6.9, 8.0, 7.0, and 7.5 ng/ μ L respectively.


626
 627



628
629

630 FIG. 6. Comparison of Electrochemiluminescent assay responses to the three *B. anthracis delta*
631 Sterne post growth treatments, Ultra Pure (Δ , n=26), 1X Wash (\diamond , n=24), Gamma Irradiated (\square ,
632 n=26), and the *B. anthracis delta* Sterne, lot AGD0000574, Critical Reagents Program reference
633 material (\circ , n=3). Sample means and standard error (bars) are shown.

634
635



636
637

638 FIG. 7. Responses of ELISA assay to the three *B. anthracis delta* Sterne treatments, Ultra Pure
 639 (Δ , n=18), 1X Wash (\diamond , n=18), Gamma Irradiated (\square , n=18), and the Critical Reagents Program
 640 reference material (\circ , n=18). *B. anthracis delta* Sterne, lot AGD0000574, sample means and
 641 standard error (bars) are shown. Each data set has a log-linear function with greater than 0.999
 642 R^2 fit across concentrations tested.

643
644

645